- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
U.S. Patent and Trademark Office has granted to Todos Medical two additional patents
Todos Medical (OTCQB:TOMDF) a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer, announced today that the U.S. Patent and Trademark Office has granted to Todos Medical two patents for broader claims for its inventions. As quoted in the press release: The first patent is titled, Biochemical Analysis …
Todos Medical (OTCQB:TOMDF) a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer, announced today that the U.S. Patent and Trademark Office has granted to Todos Medical two patents for broader claims for its inventions.
As quoted in the press release:
The first patent is titled, Biochemical Analysis of PBMCs (US 9,606,057 B2). The patent relates to analysis of an infrared spectrum of a peripheral blood mononuclear cells sample to indicate the presence of a solid tumor in breast tissue.
The second patent is titled, Infrared Analysis of Benign Tumors (US 9,804,145 B2). The patent covers Todos Medical’s innovative TBIA technology applied to differentiate between benign and malignant tumors.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â